EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte Studie

Ponatinib–Blinatumomab or Imatinib–Chemotherapy for Adult Ph-Positive ALL

Sabina Chiaretti, Alfonso Piciocchi, Cristina Skert, Matteo Leoncin, Erika Borlenghi, Chiara Cattaneo, Mariangela Di Trani, Loredana Elia, Giada Almici, Deborah Cardinali, Francesca Kaiser, Federico Lussana und 46 weitere

New England Journal of Medicine · 15.10.2026 · 395 (15) · 1483-1494

DOI: 10.1056/nejmoa2606208 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 15.10.2026. Verfasst von Sabina Chiaretti und 57 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antineoplastic Combined Chemotherapy Protocols, Imatinib Mesylate, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Associazione Italiana per la Ricerca sul Cancro, Finanziamento Medi Progetti Universitari, Progetti di Rilevante Interesse Nazionale.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificAntineoplastic Combined Chemotherapy ProtocolsImatinib MesylatePrecursor Cell Lymphoblastic Leukemia-LymphomaTyrosine Kinase InhibitorsNeoplasm Recurrence, LocalAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedYoung AdultCross-Over StudiesImidazolesKaplan-Meier EstimateNeoplasm, ResidualPhiladelphia ChromosomePyridazinesProgression-Free SurvivalFollow-Up StudiesIncidenceHematopoietic Stem Cell Transplantation

Substanzen

Antibodies, BispecificblinatumomabImatinib MesylateImidazolesponatinibPyridazinesTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome.
  • GIMEMA Data Center, Fondazione GIMEMA, Rome.
  • Hematology Unit, Ospedale dell'Angelo, Mestre Venice, Italy.
  • Division of Hematology, Azienda Socio Sanitaria Territoriale (ASST) Spedali Civili of Brescia, Brescia, Italy.
  • Department of Oncology and Hematology, University of Milan and ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Hematology Unit, Azienda Ospedaliero Universitaria (AOU) G. Rodolico-S. Marco, Catania, Italy.

ORCID-Profile: Massimiliano Bonifacio, Robin Foà

Förderung

  • Associazione Italiana per la Ricerca sul Cancro
  • Finanziamento Medi Progetti Universitari
  • Progetti di Rilevante Interesse Nazionale

Zitieren

APA

Chiaretti, S., Piciocchi, A., Skert, C., Leoncin, M., Borlenghi, E., Cattaneo, C., Di Trani, M., Elia, L., Almici, G., Cardinali, D., Kaiser, F., Lussana, F., Fiumara, P. F., Maugeri, C., Alati, C., Martino, M., Ansuinelli, M., Lucco Navei, G., Mattei, D., …, & GIMEMA Investigators (2026). Ponatinib–Blinatumomab or Imatinib–Chemotherapy for Adult Ph-Positive ALL. New England Journal of Medicine, 395(15), 1483-1494. https://doi.org/10.1056/nejmoa2606208

Vancouver

Chiaretti S, Piciocchi A, Skert C, Leoncin M, Borlenghi E, Cattaneo C, et al. Ponatinib–Blinatumomab or Imatinib–Chemotherapy for Adult Ph-Positive ALL. New England Journal of Medicine. 2026;395(15):1483-1494. doi:10.1056/nejmoa2606208

BibTeX
@article{Chiaretti2026,
  author = {Chiaretti, Sabina and Piciocchi, Alfonso and Skert, Cristina and Leoncin, Matteo and Borlenghi, Erika and Cattaneo, Chiara and Di Trani, Mariangela and Elia, Loredana and Almici, Giada and Cardinali, Deborah and Kaiser, Francesca and Lussana, Federico and Fiumara, Paolo Fabio and Maugeri, Cinzia and Alati, Caterina and Martino, Massimo and Ansuinelli, Michela and Lucco Navei, Giulia and Mattei, Daniele and Soddu, Stefano and Messina, Monica and Marino, Martina R and Mancini, Valentina and Chiusolo, Patrizia and Scappini, Barbara and Martelli, Maria P and Salutari, Prassede and Cerrano, Marco and Serio, Bianca and Cucca, Antonella and Luppi, Mario and Pochintesta, Lara and Pasciolla, Crescenza and Romani, Claudio and Mosna, Federico and Bonifacio, Massimiliano and Tanasi, Ilaria and Fracchiolla, Nicola S and Bocchia, Monica and Imbergamo, Silvia and Califano, Catello and Nunziata, Giuseppe R and Annunziata, Mario and Mulé, Antonino and Zappasodi, Patrizia and Mastaglio, Sara and Butera, Sara and Della Porta, Matteo G and Porretto, Ferdinando and Lunghi, Monia and De Bellis, Eleonora and Todisco, Elisabetta and Basilico, Claudia M and Fazi, Paola and Rambaldi, Alessandro and Bassan, Renato and Foà, Robin and GIMEMA Investigators, GIMEMA Investigators},
  title = {Ponatinib–Blinatumomab or Imatinib–Chemotherapy for Adult Ph-Positive ALL},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {15},
  pages = {1483--1494},
  doi = {10.1056/nejmoa2606208}
}
Kostenlos starten →